MPSC Sponsors Neonatal Ventilation Workshop
MPSC is proud to sponsor the Neonatal Ventilation Workshop presented in association with The Kingdom of Bahrain Ministry of Health and Arabian Gulf University. This workshop will be held February 5th-8th, 2015 at the Arabian Gulf University.
MPSC to exhibit at 3rd Regional DC/MD/VA Neonatal-Perinatal Symposium
MPSC is proud to be an exhibitor at the upcoming 3rd Regional DC/MD/VA Neonatal-Perinatal Symposium to be held October 30, 2014 at the Bethesda North Marriott Hotel and Conference Center. We will be demonstrating the new, standalone HeRO duet monitor.
HeRO duet to be shown at the Advances in Neonatal-Perinatal Medicine CME in Philadelphia
MPSC is proud to join our local representatives, Infamed, at the Advances in Neonatal-Perinatal Medicine CME course in Philadelphia, Pennsylvania. This educational meeting is being hosted by the highly regarded Children’s Hospital of Philadelphia. MPSC will be demonstrating the standalone HeRO duet monitor. Please come and speak with us.
HeRO exhibiting at the FANNP 2014 conference
MPSC was proud to exhibit the HeRO duet monitor at the Florida Association of Neonatal Nurse Practitioner’s Conference held at the Sheraton Sand Key Resort October 14-18 in Clearwater Beach, Florida. We were delighted to join our local representatives, Bimeco Group, to demonstrate the HeRO System at this educational conference.
HeRO presentation at SIGNEC
Dr. Karen Fairchild* from the University of Virginia will be presenting “Heart Rate and Cardiorespiratory Analysis for Early Detection of NEC” at the 2nd International Conference on NEC: SIGNEC UK held on Sept 3rd & 4th, 2014 in London.
*Dr. Fairchild is not a paid representative of MPSC nor has any other conflict of interest with HeRO or MPSC, the producer of HeRO.
HeRO to attend the NANN conference
HeRO will be exhibited at the upcoming NANN conference in Phoenix, Arizona. Please stop by at booth #338.
MPSC Releases HeRO Solo for Monitoring NICU Patient Distress
Medical Predictive Science Corporation has broadened its portfolio of life-saving neonatal monitors with HeRO Solo – a turnkey single patient HeRO monitor. HeRO monitors detect early signs of distress in NICU patients, commonly caused by infection and other potentially life-threatening illnesses. In the largest randomized controlled trial ever published among NICU patients, HeRO monitoring reduced mortality by 22%.
Charlottesville, Va. (PRWEB), May 28, 2014 – Medical Predictive Science Corporation announced the immediate release for sale of HeRO Solo, the latest product in the life-saving line of HeRO NICU patient monitoring devices.
“Standing alongside HeRO Symphony, HeRO ES, and HeRO Duet, we now fill out our product portfolio with HeRO Solo,” remarked CEO Will King. He added, “HeRO Solo provides our customers the same life-saving algorithm present in all HeRO products, now in a form factor that simplifies installation and clinical usage to the maximum possible extent.”
HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient’s heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded.
HeRO monitoring was extensively tested in the largest randomized controlled trial of neonatal patients ever published. In that landmark study, mortality was reduced by 22% percent among those premature infants that received HeRO monitoring, compared with those that did not.
“HeRO Solo will reach a new clinical audience. We expect widespread adoption both outside the US where networking infrastructure in the NICU is less prevalent, as well as inside the US where the move to single bed rooms necessitates bedside monitoring solutions. HeRO Solo will fill both niches,” commented Executive Vice President Geoff Alms.
To learn more about HeRO monitoring, visit www.heroscore.com.
About MPSC
MPSC is an entrepreneurial medical device company that translates ICU research discoveries to the patient’s bedside. The company develops predictive technology that detects imminent, catastrophic illness. MPSC’s HeRO monitor is the first of a line of products to monitor in-hospital patients.
Contact Information
Media contact
Geoff Alms
434.220.0714 x114
www.heroscore.com
###
ITV report – “New technology could help save premature babies’ lives”
17 March 2014 – ITV news speaks with Dr. Banerjee about HeRO from Singleton Hospital in Wales. http://www.itv.com/news/wales/story/2014-03-17/new-technology-could-save-premature-babies-lives/.
MPSC completes first installation in Wales
MPSC is pleased to welcome Singleton Hospital in Wales to the growing family of HeRO users. We are very proud to work with our partner, SLE Ltd, which represents MPSC in the United Kingdom. SLE helped the customer to successfully receive an innovation grant to deploy the HeRO System in their NICU.
Three more HeRO publications in the press.
A trio of new publications regarding HeRO hits the press. HeRO Publications lists the HeRO bibliography.
The body of evidence for HeRO continues to grow.
Further evidence of the effectiveness of HeRO is published in the Journal of Clinical Monitoring:
Complex signals bioinformatics: evaluation of heart rate characteristics monitoring as a novel risk marker for neonatal sepsis.
HeRO duet begins volume shipments.
Pallets of HeRO duets awaiting international pickup.
HeRO has been translated into French, Italian, Russian, and Turkish
HeRO is now Multi-lingual!
In response to the increasing demand for HeRO outside of the US, HeRO is now available supporting French, Italian, Russian, and Turkish. Look for more languages to be supported soon!
Customer Experience with HeRO reported in Neonatology Today
MPSC announces that Dr. Stefan Maxwell, a long-time neonatologist user of HeRO, has published an article in Neonatology Today telling his experiences with HeRO.
HeRO video
The HeRO System in use at Timpanogos Regional Medical Center in Orem, Utah.
HeRO to exhibit at PAS 2014 meeting
MPSC will be exhibiting at the Pediatric Academic Societies 2014 Annual Meeting to be held in Vancouver, BC, Canada. May 3-6, 2014.
HeRO to be presented at MEDNAX meeting
MPSC will be exhibiting HeRO at the Innovations in Neonatal Care: The Surgical Neonate and Fetus meeting held by Pediatrix Medical Group. September 18-20, 2013 at the Grand Hyatt, San Antonio, TX.
Canadian Patent issued
MPSC announces that Canada Patent No. 2476607 has been issued further extending the intellectual property protection of the HeRO algorithms.
MPSC receives order for HeRO from Italy
MPSC announces that our Italian distributor, Euromed Italy, has placed an order for HeRO duet. We are proud of this collaboration to introduce HeRO into the Italian Market.
Introducing HeRO duet
MPSC is proud to announce the newest member of the HeRO family – HeRO duet.
HeRO duet responds to the requests from our customers for a bedside version of the HeRO System. Using a touchscreen monitor for the interface, HeRO duet is simple to use and install. It was designed to be self-installed at the hospital. Each HeRO duet monitor connects to up to 2 physiological monitors. It supports data collection from the majority of physiological monitors.
HeRO order for delivery to Turkey
MPSC receives the first order for HeRO duet to be delivered to customers in Turkey.
New Publication about HeRO
Adding to the body of peer-reviewed published literature about HeRO:
Septicemia mortality reduction in neonates in a heart rate characteristics monitoring trial.
Fairchild KD, Schelonka RL, Kaufman DA, Carlo WA, Kattwinkel J, Porcelli PJ, Navarrete CT, Bancalari E, Aschner JL, Walker MW, Perez JA, Palmer C, Lake DE, O’Shea TM, Moorman JR.
Pediatr Res. (2013) Aug 13. doi: 10.1038/pr.2013.136.
MPSC completes first sale in the United Kingdom
MPSC is proud to announce that the first installation of HeRO in the United Kingdom has been completed.
HeRO System Receives Canadian Medical Device License
CHARLOTTESVILLE, Va., December 3, 2012 Medical Predictive Science Corporation (MPSC) announces that it has received a Medical Device License from Health Canada for the Heart Rate Observation System, or HeRO® System. This license allows the device to be marketed and sold in Canada indicated for the prediction of sepsis and improvement in mortality.
MPSC CEO Will King commented, “MPSC is very proud to continue building upon the international acceptance of the HeRO System as a safe and effective medical device for infants in the neonatal intensive care units. Adding to the recently received CE marking, HeRO may now be marketed in the European Union, Canada, and the United States.”
“MPSC looks to continue upon our recent successes with regulatory submissions in additional countries. HeRO is a quality product supported by the evidence from a large clinical trial which clearly demonstrated safety and effectiveness.” noted Ray Schumin, Director of Regulatory Affairs. “We are very pleased for the receipt of this license from Health Canada,” he added.
“MPSC is immediately looking to engage partners or distributors in Canada that want to introduce this life-saving technology into Canadian NICUs. We look to fulfill the requests of potential customers in Canada who have expressed significant interest in the HeRO System and had been eagerly awaiting the availability of HeRO,” remarked Geoff Alms, PhD, Exec. VP of Sales and Marketing.
HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient’s heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded.
About MPSC
MPSC is an entrepreneurial medical device company that translates ICU research discoveries to the patient’s bedside. The company develops predictive technology that detects imminent, catastrophic illness. MPSC’s HeRO monitor is the first of a line of products to monitor in-hospital patients.